OA12000A - Pyrimidine-2,4,6-trione metalloproteinase inhibitors. - Google Patents

Pyrimidine-2,4,6-trione metalloproteinase inhibitors. Download PDF

Info

Publication number: OA12000A
Authority: OA; OAPI
Prior art keywords: daim; compound according; oxygen; phenoxy; trione
Prior art date: 1999-08-12

Application number

OA1200200030A

Other languages

English (en)

Inventor

Julian Blagg

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-08-12

Filing date

2000-08-03

Publication date

2006-04-18

2000-08-03 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2006-04-18 Publication of OA12000A publication Critical patent/OA12000A/en

Links

HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 title abstract description 4
239000003475 metalloproteinase inhibitor Substances 0.000 title abstract description 4
238000000034 method Methods 0.000 claims abstract description 27
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 21
206010028980 Neoplasm Diseases 0.000 claims abstract description 14
201000011510 cancer Diseases 0.000 claims abstract description 11
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 8
150000001875 compounds Chemical class 0.000 claims description 183
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 61
229910052760 oxygen Inorganic materials 0.000 claims description 61
239000001301 oxygen Substances 0.000 claims description 61
-1 Y is a bond Substances 0.000 claims description 57
125000000217 alkyl group Chemical group 0.000 claims description 34
230000005764 inhibitory process Effects 0.000 claims description 26
229910052739 hydrogen Inorganic materials 0.000 claims description 23
239000001257 hydrogen Substances 0.000 claims description 23
102000002274 Matrix Metalloproteinases Human genes 0.000 claims description 22
108010000684 Matrix Metalloproteinases Proteins 0.000 claims description 22
125000003118 aryl group Chemical group 0.000 claims description 22
238000006243 chemical reaction Methods 0.000 claims description 22
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 19
125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 18
229910052717 sulfur Inorganic materials 0.000 claims description 18
239000011593 sulfur Substances 0.000 claims description 18
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 16
201000010099 disease Diseases 0.000 claims description 16
125000005842 heteroatom Chemical group 0.000 claims description 16
125000003545 alkoxy group Chemical group 0.000 claims description 15
125000001424 substituent group Chemical group 0.000 claims description 15
238000011282 treatment Methods 0.000 claims description 15
125000001072 heteroaryl group Chemical group 0.000 claims description 14
241000124008 Mammalia Species 0.000 claims description 9
125000004432 carbon atom Chemical group C* 0.000 claims description 9
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 9
ZSHDPGCEJWXJLC-UHFFFAOYSA-N N-methyl-N-naphthalen-2-yl-2,3-dioxoquinoxaline-6-sulfonamide Chemical compound CN(c1ccc2ccccc2c1)S(=O)(=O)c1ccc2=NC(=O)C(=O)N=c2c1 ZSHDPGCEJWXJLC-UHFFFAOYSA-N 0.000 claims description 8
125000003282 alkyl amino group Chemical group 0.000 claims description 8
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 8
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 8
125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 7
206010020751 Hypersensitivity Diseases 0.000 claims description 7
230000007815 allergy Effects 0.000 claims description 7
208000007474 aortic aneurysm Diseases 0.000 claims description 7
229910052801 chlorine Inorganic materials 0.000 claims description 7
229910052794 bromium Inorganic materials 0.000 claims description 6
229910052731 fluorine Inorganic materials 0.000 claims description 6
238000004519 manufacturing process Methods 0.000 claims description 6
210000001519 tissue Anatomy 0.000 claims description 6
208000023275 Autoimmune disease Diseases 0.000 claims description 5
206010040047 Sepsis Diseases 0.000 claims description 5
206010040070 Septic Shock Diseases 0.000 claims description 5
208000027418 Wounds and injury Diseases 0.000 claims description 5
206010003246 arthritis Diseases 0.000 claims description 5
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
230000036303 septic shock Effects 0.000 claims description 5
208000030507 AIDS Diseases 0.000 claims description 4
206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 4
206010002027 Amyotrophy Diseases 0.000 claims description 4
206010006895 Cachexia Diseases 0.000 claims description 4
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 4
208000011231 Crohn disease Diseases 0.000 claims description 4
206010014561 Emphysema Diseases 0.000 claims description 4
206010019196 Head injury Diseases 0.000 claims description 4
208000023105 Huntington disease Diseases 0.000 claims description 4
208000019695 Migraine disease Diseases 0.000 claims description 4
208000001132 Osteoporosis Diseases 0.000 claims description 4
208000002193 Pain Diseases 0.000 claims description 4
208000018737 Parkinson disease Diseases 0.000 claims description 4
208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 4
230000002159 abnormal effect Effects 0.000 claims description 4
201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 4
230000033115 angiogenesis Effects 0.000 claims description 4
208000006673 asthma Diseases 0.000 claims description 4
208000010247 contact dermatitis Diseases 0.000 claims description 4
125000000753 cycloalkyl group Chemical group 0.000 claims description 4
239000007943 implant Substances 0.000 claims description 4
208000028867 ischemia Diseases 0.000 claims description 4
206010027599 migraine Diseases 0.000 claims description 4
208000010125 myocardial infarction Diseases 0.000 claims description 4
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 4
230000001777 nootropic effect Effects 0.000 claims description 4
125000005010 perfluoroalkyl group Chemical group 0.000 claims description 4
208000033808 peripheral neuropathy Diseases 0.000 claims description 4
208000037803 restenosis Diseases 0.000 claims description 4
208000020431 spinal cord injury Diseases 0.000 claims description 4
231100000419 toxicity Toxicity 0.000 claims description 4
230000001988 toxicity Effects 0.000 claims description 4
230000006378 damage Effects 0.000 claims description 3
208000014674 injury Diseases 0.000 claims description 3
208000002780 macular degeneration Diseases 0.000 claims description 3
208000015122 neurodegenerative disease Diseases 0.000 claims description 3
230000037390 scarring Effects 0.000 claims description 3
FMCGEYRROGIPRL-UHFFFAOYSA-N 5-butyl-5-(4-phenoxyphenoxy)-1,3-diazinane-2,4,6-trione Chemical compound C=1C=C(OC=2C=CC=CC=2)C=CC=1OC1(CCCC)C(=O)NC(=O)NC1=O FMCGEYRROGIPRL-UHFFFAOYSA-N 0.000 claims description 2
239000003937 drug carrier Substances 0.000 claims description 2
210000000056 organ Anatomy 0.000 claims description 2
SGPGESCZOCHFCL-UHFFFAOYSA-N Tilisolol hydrochloride Chemical compound [Cl-].C1=CC=C2C(=O)N(C)C=C(OCC(O)C[NH2+]C(C)(C)C)C2=C1 SGPGESCZOCHFCL-UHFFFAOYSA-N 0.000 claims 34
BGCPLWWYPZAURQ-UHFFFAOYSA-N 5-[[5-chloro-2-(2,2,6,6-tetramethylmorpholin-4-yl)pyrimidin-4-yl]amino]-3-(3-hydroxy-3-methylbutyl)-1-methylbenzimidazol-2-one Chemical compound ClC=1C(=NC(=NC=1)N1CC(OC(C1)(C)C)(C)C)NC1=CC2=C(N(C(N2CCC(C)(C)O)=O)C)C=C1 BGCPLWWYPZAURQ-UHFFFAOYSA-N 0.000 claims 3
206010059245 Angiopathy Diseases 0.000 claims 2
206010007559 Cardiac failure congestive Diseases 0.000 claims 2
206010014989 Epidermolysis bullosa Diseases 0.000 claims 2
206010019280 Heart failures Diseases 0.000 claims 2
208000006011 Stroke Diseases 0.000 claims 2
125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 1
DYYXNPHKNSXHPG-UHFFFAOYSA-N 5-methyl-5-(3-phenylphenoxy)-1,3-diazinane-2,4,6-trione Chemical compound C=1C=CC(C=2C=CC=CC=2)=CC=1OC1(C)C(=O)NC(=O)NC1=O DYYXNPHKNSXHPG-UHFFFAOYSA-N 0.000 claims 1
MUGKSTGYZUUSRY-UHFFFAOYSA-N 5-methyl-5-(4-phenoxyphenoxy)-1,3-diazinane-2,4,6-trione Chemical compound C=1C=C(OC=2C=CC=CC=2)C=CC=1OC1(C)C(=O)NC(=O)NC1=O MUGKSTGYZUUSRY-UHFFFAOYSA-N 0.000 claims 1
208000024827 Alzheimer disease Diseases 0.000 claims 1
125000000041 C6-C10 aryl group Chemical group 0.000 claims 1
125000000000 cycloalkoxy group Chemical group 0.000 claims 1
208000035475 disorder Diseases 0.000 abstract description 5
206010061218 Inflammation Diseases 0.000 abstract description 2
230000004054 inflammatory process Effects 0.000 abstract description 2
229910052727 yttrium Inorganic materials 0.000 abstract description 2
239000003112 inhibitor Substances 0.000 description 54
102000004190 Enzymes Human genes 0.000 description 45
108090000790 Enzymes Proteins 0.000 description 45
229940088598 enzyme Drugs 0.000 description 45
238000003556 assay Methods 0.000 description 38
239000002585 base Substances 0.000 description 29
150000003839 salts Chemical class 0.000 description 28
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 22
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 21
230000000694 effects Effects 0.000 description 20
239000000758 substrate Substances 0.000 description 20
102100027995 Collagenase 3 Human genes 0.000 description 19
108050005238 Collagenase 3 Proteins 0.000 description 17
238000010790 dilution Methods 0.000 description 17
239000012895 dilution Substances 0.000 description 17
239000000243 solution Substances 0.000 description 17
239000003814 drug Substances 0.000 description 16
102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 15
108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 15
239000002253 acid Substances 0.000 description 15
229940079593 drug Drugs 0.000 description 15
229920001436 collagen Polymers 0.000 description 14
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 13
108010035532 Collagen Proteins 0.000 description 13
102000008186 Collagen Human genes 0.000 description 13
238000007792 addition Methods 0.000 description 13
210000000845 cartilage Anatomy 0.000 description 13
239000003795 chemical substances by application Substances 0.000 description 13
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
125000005843 halogen group Chemical group 0.000 description 12
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 12
239000012131 assay buffer Substances 0.000 description 11
210000004027 cell Anatomy 0.000 description 11
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 10
239000000203 mixture Substances 0.000 description 10
239000002904 solvent Substances 0.000 description 10
239000011550 stock solution Substances 0.000 description 10
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 10
108091007505 ADAM17 Proteins 0.000 description 9
102000043279 ADAM17 Human genes 0.000 description 9
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
102000004142 Trypsin Human genes 0.000 description 9
108090000631 Trypsin Proteins 0.000 description 9
108060008682 Tumor Necrosis Factor Proteins 0.000 description 9
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 9
108010003059 aggrecanase Proteins 0.000 description 9
239000000651 prodrug Substances 0.000 description 9
229940002612 prodrug Drugs 0.000 description 9
239000012588 trypsin Substances 0.000 description 9
102000029791 ADAM Human genes 0.000 description 8
108091022885 ADAM Proteins 0.000 description 8
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 8
125000001309 chloro group Chemical group Cl* 0.000 description 8
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 7
239000007983 Tris buffer Substances 0.000 description 7
150000001768 cations Chemical class 0.000 description 7
239000003153 chemical reaction reagent Substances 0.000 description 7
239000011159 matrix material Substances 0.000 description 7
239000012312 sodium hydride Substances 0.000 description 7
229910000104 sodium hydride Inorganic materials 0.000 description 7
MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 6
ORILYTVJVMAKLC-UHFFFAOYSA-N Adamantane Natural products C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 6
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 6
102000005741 Metalloproteases Human genes 0.000 description 6
108010006035 Metalloproteases Proteins 0.000 description 6
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 6
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 6
230000015572 biosynthetic process Effects 0.000 description 6
239000000460 chlorine Substances 0.000 description 6
231100000252 nontoxic Toxicity 0.000 description 6
230000003000 nontoxic effect Effects 0.000 description 6
229910000027 potassium carbonate Inorganic materials 0.000 description 6
QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 5
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
229940124761 MMP inhibitor Drugs 0.000 description 5
102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 5
108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 5
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 5
CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Substances CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 5
CSCPPACGZOOCGX-WFGJKAKNSA-N acetone d6 Chemical compound [2H]C([2H])([2H])C(=O)C([2H])([2H])[2H] CSCPPACGZOOCGX-WFGJKAKNSA-N 0.000 description 5
150000007513 acids Chemical class 0.000 description 5
125000001246 bromo group Chemical group Br* 0.000 description 5
229910052799 carbon Inorganic materials 0.000 description 5
230000005284 excitation Effects 0.000 description 5
239000002609 medium Substances 0.000 description 5
201000008482 osteoarthritis Diseases 0.000 description 5
125000003373 pyrazinyl group Chemical group 0.000 description 5
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 5
206010039073 rheumatoid arthritis Diseases 0.000 description 5
239000011734 sodium Substances 0.000 description 5
229910052708 sodium Inorganic materials 0.000 description 5
238000003786 synthesis reaction Methods 0.000 description 5
VKUYLANQOAKALN-UHFFFAOYSA-N 2-[benzyl-(4-methoxyphenyl)sulfonylamino]-n-hydroxy-4-methylpentanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(CC(C)C)C(=O)NO)CC1=CC=CC=C1 VKUYLANQOAKALN-UHFFFAOYSA-N 0.000 description 4
NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical class C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 description 4
ZSBDGXGICLIJGD-UHFFFAOYSA-N 4-phenoxyphenol Chemical compound C1=CC(O)=CC=C1OC1=CC=CC=C1 ZSBDGXGICLIJGD-UHFFFAOYSA-N 0.000 description 4
102100026802 72 kDa type IV collagenase Human genes 0.000 description 4
101710151806 72 kDa type IV collagenase Proteins 0.000 description 4
241000283690 Bos taurus Species 0.000 description 4
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 4
PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 4
208000012659 Joint disease Diseases 0.000 description 4
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
238000005481 NMR spectroscopy Methods 0.000 description 4
229910019142 PO4 Inorganic materials 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
102100030416 Stromelysin-1 Human genes 0.000 description 4
101710108790 Stromelysin-1 Proteins 0.000 description 4
150000001298 alcohols Chemical class 0.000 description 4
239000002168 alkylating agent Substances 0.000 description 4
229940100198 alkylating agent Drugs 0.000 description 4
210000001612 chondrocyte Anatomy 0.000 description 4
PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 4
229940093499 ethyl acetate Drugs 0.000 description 4
235000019439 ethyl acetate Nutrition 0.000 description 4
229960002591 hydroxyproline Drugs 0.000 description 4
210000002184 nasal cartilage Anatomy 0.000 description 4
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
239000010452 phosphate Substances 0.000 description 4
239000002798 polar solvent Substances 0.000 description 4
125000004076 pyridyl group Chemical group 0.000 description 4
238000012360 testing method Methods 0.000 description 4
125000001412 tetrahydropyranyl group Chemical group 0.000 description 4
FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 4
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 4
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 3
OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 3
108010076503 Matrix Metalloproteinase 13 Proteins 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
229920002472 Starch Polymers 0.000 description 3
102100040247 Tumor necrosis factor Human genes 0.000 description 3
230000029936 alkylation Effects 0.000 description 3
238000005804 alkylation reaction Methods 0.000 description 3
125000004429 atom Chemical group 0.000 description 3
239000000872 buffer Substances 0.000 description 3
239000011575 calcium Substances 0.000 description 3
229910052791 calcium Inorganic materials 0.000 description 3
239000004202 carbamide Substances 0.000 description 3
125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 3
229910002092 carbon dioxide Inorganic materials 0.000 description 3
238000003271 compound fluorescence assay Methods 0.000 description 3
239000003636 conditioned culture medium Substances 0.000 description 3
125000004093 cyano group Chemical group *C#N 0.000 description 3
230000029087 digestion Effects 0.000 description 3
ZMXDDKWLCZADIW-UHFFFAOYSA-N dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
239000011737 fluorine Substances 0.000 description 3
125000001153 fluoro group Chemical group F* 0.000 description 3
238000011534 incubation Methods 0.000 description 3
239000010410 layer Substances 0.000 description 3
229910052757 nitrogen Inorganic materials 0.000 description 3
239000003921 oil Substances 0.000 description 3
235000019198 oils Nutrition 0.000 description 3
230000001575 pathological effect Effects 0.000 description 3
230000002285 radioactive effect Effects 0.000 description 3
238000010992 reflux Methods 0.000 description 3
239000008107 starch Substances 0.000 description 3
235000019698 starch Nutrition 0.000 description 3
239000000126 substance Substances 0.000 description 3
239000000725 suspension Substances 0.000 description 3
125000001544 thienyl group Chemical group 0.000 description 3
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
125000006625 (C3-C8) cycloalkyloxy group Chemical group 0.000 description 2
VOYADQIFGGIKAT-UHFFFAOYSA-N 1,3-dibutyl-4-hydroxy-2,6-dioxopyrimidine-5-carboximidamide Chemical compound CCCCn1c(O)c(C(N)=N)c(=O)n(CCCC)c1=O VOYADQIFGGIKAT-UHFFFAOYSA-N 0.000 description 2
238000005160 1H NMR spectroscopy Methods 0.000 description 2
IEQAICDLOKRSRL-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEQAICDLOKRSRL-UHFFFAOYSA-N 0.000 description 2
NCQJBPXXRXOIJD-UHFFFAOYSA-N 3-[(2-methylpropan-2-yl)oxycarbonylamino]-3-naphthalen-2-ylpropanoic acid Chemical compound C1=CC=CC2=CC(C(CC(O)=O)NC(=O)OC(C)(C)C)=CC=C21 NCQJBPXXRXOIJD-UHFFFAOYSA-N 0.000 description 2
102100036601 Aggrecan core protein Human genes 0.000 description 2
108010067219 Aggrecans Proteins 0.000 description 2
206010006187 Breast cancer Diseases 0.000 description 2
208000026310 Breast neoplasm Diseases 0.000 description 2
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
102000000503 Collagen Type II Human genes 0.000 description 2
108010041390 Collagen Type II Proteins 0.000 description 2
206010009944 Colon cancer Diseases 0.000 description 2
DSLZVSRJTYRBFB-LLEIAEIESA-N D-glucaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 description 2
RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 2
YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 2
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
206010025323 Lymphomas Diseases 0.000 description 2
102100027998 Macrophage metalloelastase Human genes 0.000 description 2
101710187853 Macrophage metalloelastase Proteins 0.000 description 2
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
102000055008 Matrilin Proteins Human genes 0.000 description 2
108010072582 Matrilin Proteins Proteins 0.000 description 2
102000000422 Matrix Metalloproteinase 3 Human genes 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
229910002651 NO3 Inorganic materials 0.000 description 2
102100030411 Neutrophil collagenase Human genes 0.000 description 2
101710118230 Neutrophil collagenase Proteins 0.000 description 2
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
108090000526 Papain Proteins 0.000 description 2
229920001774 Perfluoroether Polymers 0.000 description 2
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
239000004365 Protease Substances 0.000 description 2
102000016611 Proteoglycans Human genes 0.000 description 2
108010067787 Proteoglycans Proteins 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
208000002223 abdominal aortic aneurysm Diseases 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
239000003513 alkali Substances 0.000 description 2
125000003368 amide group Chemical group 0.000 description 2
150000001412 amines Chemical class 0.000 description 2
235000001014 amino acid Nutrition 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
125000004104 aryloxy group Chemical group 0.000 description 2
150000001541 aziridines Chemical class 0.000 description 2
125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 2
125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
230000001684 chronic effect Effects 0.000 description 2
238000003776 cleavage reaction Methods 0.000 description 2
230000019771 cognition Effects 0.000 description 2
208000029742 colonic neoplasm Diseases 0.000 description 2
229940111134 coxibs Drugs 0.000 description 2
239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 2
229910052805 deuterium Inorganic materials 0.000 description 2
ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
150000002118 epoxides Chemical class 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
125000002541 furyl group Chemical group 0.000 description 2
229940050410 gluconate Drugs 0.000 description 2
230000003394 haemopoietic effect Effects 0.000 description 2
239000012456 homogeneous solution Substances 0.000 description 2
229920002674 hyaluronan Polymers 0.000 description 2
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 2
125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
238000000099 in vitro assay Methods 0.000 description 2
CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
230000002757 inflammatory effect Effects 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 2
125000005956 isoquinolyl group Chemical group 0.000 description 2
125000000842 isoxazolyl group Chemical group 0.000 description 2
239000008101 lactose Substances 0.000 description 2
238000002844 melting Methods 0.000 description 2
230000008018 melting Effects 0.000 description 2
229960000485 methotrexate Drugs 0.000 description 2
NBTOZLQBSIZIKS-UHFFFAOYSA-N methoxide Chemical compound [O-]C NBTOZLQBSIZIKS-UHFFFAOYSA-N 0.000 description 2
210000001616 monocyte Anatomy 0.000 description 2
150000007524 organic acids Chemical class 0.000 description 2
239000012044 organic layer Substances 0.000 description 2
230000003349 osteoarthritic effect Effects 0.000 description 2
229940055729 papain Drugs 0.000 description 2
235000019834 papain Nutrition 0.000 description 2
208000028169 periodontal disease Diseases 0.000 description 2
125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 2
125000004193 piperazinyl group Chemical group 0.000 description 2
125000003386 piperidinyl group Chemical group 0.000 description 2
239000013641 positive control Substances 0.000 description 2
239000011591 potassium Substances 0.000 description 2
229910052700 potassium Inorganic materials 0.000 description 2
239000000843 powder Substances 0.000 description 2
235000018102 proteins Nutrition 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
125000003226 pyrazolyl group Chemical group 0.000 description 2
125000005493 quinolyl group Chemical group 0.000 description 2
UHSKFQJFRQCDBE-UHFFFAOYSA-N ropinirole Chemical compound CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2 UHSKFQJFRQCDBE-UHFFFAOYSA-N 0.000 description 2
230000007017 scission Effects 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
230000000638 stimulation Effects 0.000 description 2
108091007196 stromelysin Proteins 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
239000000829 suppository Substances 0.000 description 2
229940095064 tartrate Drugs 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
125000000335 thiazolyl group Chemical group 0.000 description 2
125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 2
230000004614 tumor growth Effects 0.000 description 2
230000029663 wound healing Effects 0.000 description 2
JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 description 1
125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 1
BPXVHIRIPLPOPT-UHFFFAOYSA-N 1,3,5-tris(2-hydroxyethyl)-1,3,5-triazinane-2,4,6-trione Chemical compound OCCN1C(=O)N(CCO)C(=O)N(CCO)C1=O BPXVHIRIPLPOPT-UHFFFAOYSA-N 0.000 description 1
ZPNCIRQGIISPNO-UHFFFAOYSA-N 2-(4-phenoxyphenoxy)propanedioic acid Chemical compound C1=CC(OC(C(=O)O)C(O)=O)=CC=C1OC1=CC=CC=C1 ZPNCIRQGIISPNO-UHFFFAOYSA-N 0.000 description 1
BRMWTNUJHUMWMS-UHFFFAOYSA-N 3-Methylhistidine Natural products CN1C=NC(CC(N)C(O)=O)=C1 BRMWTNUJHUMWMS-UHFFFAOYSA-N 0.000 description 1
TVZDWYYXHAIMCR-UHFFFAOYSA-N 4-[[2-[[1-[6-amino-2-[[1-[5-carbamimidamido-2-[[2-(7-methoxy-2-oxochromen-4-yl)acetyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-5-[[1-[[1-[[1-[[1-amino-6-(2,4-dinitroanilino)-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopentan-2-yl]amino]-5-oxopentanoic acid Chemical compound CCCC(NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C1CCCN1C(=O)C(CCCCN)NC(=O)C1CCCN1C(=O)C(CCCNC(N)=N)NC(=O)CC1=CC(=O)Oc2cc(OC)ccc12)C(C)C)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(CCCNC(N)=N)C(=O)NC(CCCCNc1ccc(cc1[N+]([O-])=O)[N+]([O-])=O)C(N)=O TVZDWYYXHAIMCR-UHFFFAOYSA-N 0.000 description 1
PMMYEEVYMWASQN-BKLSDQPFSA-N 4-hydroxy-L-proline Chemical compound OC1C[NH2+][C@H](C([O-])=O)C1 PMMYEEVYMWASQN-BKLSDQPFSA-N 0.000 description 1
PJJGZPJJTHBVMX-UHFFFAOYSA-N 5,7-Dihydroxyisoflavone Chemical compound C=1C(O)=CC(O)=C(C2=O)C=1OC=C2C1=CC=CC=C1 PJJGZPJJTHBVMX-UHFFFAOYSA-N 0.000 description 1
KHRUCVAJVVHQHT-UHFFFAOYSA-N 5-(4-phenoxyphenoxy)-1,3-diazinane-2,4,6-trione Chemical compound O=C1NC(=O)NC(=O)C1OC(C=C1)=CC=C1OC1=CC=CC=C1 KHRUCVAJVVHQHT-UHFFFAOYSA-N 0.000 description 1
NKCOKPPDVGALJW-UHFFFAOYSA-N 5-[4-(4-fluorophenoxy)phenoxy]-1,3-diazinane-2,4,6-trione Chemical compound C1=CC(F)=CC=C1OC(C=C1)=CC=C1OC1C(=O)NC(=O)NC1=O NKCOKPPDVGALJW-UHFFFAOYSA-N 0.000 description 1
NWCKCEKCHDFGDI-UHFFFAOYSA-N 5-[4-(cyclopropylmethoxy)phenoxy]-5-methyl-1,3-diazinane-2,4,6-trione Chemical compound C=1C=C(OCC2CC2)C=CC=1OC1(C)C(=O)NC(=O)NC1=O NWCKCEKCHDFGDI-UHFFFAOYSA-N 0.000 description 1
FSDNTAHYLWYSPC-UHFFFAOYSA-N 5-methyl-5-(4-phenylmethoxyphenoxy)-1,3-diazinane-2,4,6-trione Chemical compound C=1C=C(OCC=2C=CC=CC=2)C=CC=1OC1(C)C(=O)NC(=O)NC1=O FSDNTAHYLWYSPC-UHFFFAOYSA-N 0.000 description 1
VDKHADFUPYVSNE-UHFFFAOYSA-N 5-methyl-5-(4-pyridin-2-ylphenoxy)-1,3-diazinane-2,4,6-trione Chemical compound C=1C=C(C=2N=CC=CC=2)C=CC=1OC1(C)C(=O)NC(=O)NC1=O VDKHADFUPYVSNE-UHFFFAOYSA-N 0.000 description 1
QSMFWJGXWVXSLH-UHFFFAOYSA-N 5-methyl-5-(4-pyridin-4-ylphenoxy)-1,3-diazinane-2,4,6-trione Chemical compound C=1C=C(C=2C=CN=CC=2)C=CC=1OC1(C)C(=O)NC(=O)NC1=O QSMFWJGXWVXSLH-UHFFFAOYSA-N 0.000 description 1
STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
239000005541 ACE inhibitor Substances 0.000 description 1
102000051388 ADAMTS1 Human genes 0.000 description 1
108091005660 ADAMTS1 Proteins 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
229940124810 Alzheimer's drug Drugs 0.000 description 1
102100028116 Amine oxidase [flavin-containing] B Human genes 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
206010002329 Aneurysm Diseases 0.000 description 1
102400000068 Angiostatin Human genes 0.000 description 1
108010079709 Angiostatins Proteins 0.000 description 1
229940127398 Angiotensin 2 Receptor Antagonists Drugs 0.000 description 1
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
235000014698 Brassica juncea var multisecta Nutrition 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
239000004215 Carbon black (E152) Substances 0.000 description 1
OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
229910052684 Cerium Inorganic materials 0.000 description 1
244000089742 Citrus aurantifolia Species 0.000 description 1
235000008733 Citrus aurantifolia Nutrition 0.000 description 1
102000012422 Collagen Type I Human genes 0.000 description 1
108010022452 Collagen Type I Proteins 0.000 description 1
102100031162 Collagen alpha-1(XVIII) chain Human genes 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
235000019739 Dicalciumphosphate Nutrition 0.000 description 1
239000004338 Dichlorodifluoromethane Substances 0.000 description 1
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
101800001224 Disintegrin Proteins 0.000 description 1
ZQZFYGIXNQKOAV-OCEACIFDSA-N Droloxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=C(O)C=CC=1)\C1=CC=C(OCCN(C)C)C=C1 ZQZFYGIXNQKOAV-OCEACIFDSA-N 0.000 description 1
102100040278 E3 ubiquitin-protein ligase RNF19A Human genes 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
238000008157 ELISA kit Methods 0.000 description 1
108010079505 Endostatins Proteins 0.000 description 1
241000792859 Enema Species 0.000 description 1
206010053177 Epidermolysis Diseases 0.000 description 1
108010008165 Etanercept Proteins 0.000 description 1
VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
239000005977 Ethylene Substances 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
244000068988 Glycine max Species 0.000 description 1
235000010469 Glycine max Nutrition 0.000 description 1
108060003393 Granulin Proteins 0.000 description 1
239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000768078 Homo sapiens Amine oxidase [flavin-containing] B Proteins 0.000 description 1
101001011896 Homo sapiens Matrix metalloproteinase-19 Proteins 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
LCWXJXMHJVIJFK-UHFFFAOYSA-N Hydroxylysine Natural products NCC(O)CC(N)CC(O)=O LCWXJXMHJVIJFK-UHFFFAOYSA-N 0.000 description 1
HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
206010058467 Lung neoplasm malignant Diseases 0.000 description 1
101150014058 MMP1 gene Proteins 0.000 description 1
240000003183 Manihot esculenta Species 0.000 description 1
235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
102100030417 Matrilysin Human genes 0.000 description 1
108090000855 Matrilysin Proteins 0.000 description 1
108010076557 Matrix Metalloproteinase 14 Proteins 0.000 description 1
102100030216 Matrix metalloproteinase-14 Human genes 0.000 description 1
102100030201 Matrix metalloproteinase-15 Human genes 0.000 description 1
108090000560 Matrix metalloproteinase-15 Proteins 0.000 description 1
102100030200 Matrix metalloproteinase-16 Human genes 0.000 description 1
108090000561 Matrix metalloproteinase-16 Proteins 0.000 description 1
102100030219 Matrix metalloproteinase-17 Human genes 0.000 description 1
108090000585 Matrix metalloproteinase-17 Proteins 0.000 description 1
102100030218 Matrix metalloproteinase-19 Human genes 0.000 description 1
102000004055 Matrix metalloproteinase-19 Human genes 0.000 description 1
108090000587 Matrix metalloproteinase-19 Proteins 0.000 description 1
102100029693 Matrix metalloproteinase-20 Human genes 0.000 description 1
108090000609 Matrix metalloproteinase-20 Proteins 0.000 description 1
102000018697 Membrane Proteins Human genes 0.000 description 1
108010052285 Membrane Proteins Proteins 0.000 description 1
102000003843 Metalloendopeptidases Human genes 0.000 description 1
108090000131 Metalloendopeptidases Proteins 0.000 description 1
206010027476 Metastases Diseases 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
102000036436 Metzincins Human genes 0.000 description 1
108091007161 Metzincins Proteins 0.000 description 1
JDHILDINMRGULE-LURJTMIESA-N N(pros)-methyl-L-histidine Chemical compound CN1C=NC=C1C[C@H](N)C(O)=O JDHILDINMRGULE-LURJTMIESA-N 0.000 description 1
HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 1
ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
108010042992 NFF 3 Proteins 0.000 description 1
CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
206010028851 Necrosis Diseases 0.000 description 1
102000006538 Nitric Oxide Synthase Type I Human genes 0.000 description 1
108010008858 Nitric Oxide Synthase Type I Proteins 0.000 description 1
229930012538 Paclitaxel Natural products 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
RBQOQRRFDPXAGN-UHFFFAOYSA-N Propentofylline Chemical compound CN1C(=O)N(CCCCC(C)=O)C(=O)C2=C1N=CN2CCC RBQOQRRFDPXAGN-UHFFFAOYSA-N 0.000 description 1
241000251184 Rajiformes Species 0.000 description 1
206010039705 Scleritis Diseases 0.000 description 1
208000034189 Sclerosis Diseases 0.000 description 1
244000000231 Sesamum indicum Species 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
244000061456 Solanum tuberosum Species 0.000 description 1
235000002595 Solanum tuberosum Nutrition 0.000 description 1
102100028848 Stromelysin-2 Human genes 0.000 description 1
101710108792 Stromelysin-2 Proteins 0.000 description 1
102100028847 Stromelysin-3 Human genes 0.000 description 1
108050005271 Stromelysin-3 Proteins 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
239000005864 Sulphur Substances 0.000 description 1
108700012920 TNF Proteins 0.000 description 1
235000011941 Tilia x europaea Nutrition 0.000 description 1
229940122618 Trypsin inhibitor Drugs 0.000 description 1
101710162629 Trypsin inhibitor Proteins 0.000 description 1
108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
206010064390 Tumour invasion Diseases 0.000 description 1
101001011890 Xenopus laevis Matrix metalloproteinase-18 Proteins 0.000 description 1
240000008042 Zea mays Species 0.000 description 1
235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
235000002017 Zea mays subsp mays Nutrition 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
229960001138 acetylsalicylic acid Drugs 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
229940009456 adriamycin Drugs 0.000 description 1
238000004220 aggregation Methods 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
239000000556 agonist Substances 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
150000001336 alkenes Chemical group 0.000 description 1
125000003342 alkenyl group Chemical group 0.000 description 1
125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
229940051880 analgesics and antipyretics pyrazolones Drugs 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
150000001450 anions Chemical class 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
230000007131 anti Alzheimer effect Effects 0.000 description 1
229940035678 anti-parkinson drug Drugs 0.000 description 1
239000000935 antidepressant agent Substances 0.000 description 1
229940005513 antidepressants Drugs 0.000 description 1
229940111136 antiinflammatory and antirheumatic drug fenamates Drugs 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
210000001188 articular cartilage Anatomy 0.000 description 1
125000003710 aryl alkyl group Chemical group 0.000 description 1
125000005161 aryl oxy carbonyl group Chemical group 0.000 description 1
FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 1
AUJRCFUBUPVWSZ-XTZHGVARSA-M auranofin Chemical compound CCP(CC)(CC)=[Au]S[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O AUJRCFUBUPVWSZ-XTZHGVARSA-M 0.000 description 1
229960005207 auranofin Drugs 0.000 description 1
WOIIIUDZSOLAIW-NSHDSACASA-N azapropazone Chemical compound C1=C(C)C=C2N3C(=O)[C@H](CC=C)C(=O)N3C(N(C)C)=NC2=C1 WOIIIUDZSOLAIW-NSHDSACASA-N 0.000 description 1
229960001671 azapropazone Drugs 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
229940077388 benzenesulfonate Drugs 0.000 description 1
125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
239000002876 beta blocker Substances 0.000 description 1
229940097320 beta blocking agent Drugs 0.000 description 1
229940000635 beta-alanine Drugs 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
238000004166 bioassay Methods 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
230000037396 body weight Effects 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
239000007975 buffered saline Substances 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
230000009400 cancer invasion Effects 0.000 description 1
239000002775 capsule Substances 0.000 description 1
150000004657 carbamic acid derivatives Chemical class 0.000 description 1
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
150000001721 carbon Chemical group 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
229960004424 carbon dioxide Drugs 0.000 description 1
150000004649 carbonic acid derivatives Chemical class 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
229960000590 celecoxib Drugs 0.000 description 1
RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
HEDRZPFGACZZDS-UHFFFAOYSA-N chloroform Substances ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 1
229960002173 citrulline Drugs 0.000 description 1
235000013477 citrulline Nutrition 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
230000036569 collagen breakdown Effects 0.000 description 1
108700004333 collagenase 1 Proteins 0.000 description 1
238000004040 coloring Methods 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
230000001143 conditioned effect Effects 0.000 description 1
210000002808 connective tissue Anatomy 0.000 description 1
239000000470 constituent Substances 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
235000005822 corn Nutrition 0.000 description 1
239000003246 corticosteroid Substances 0.000 description 1
229960001334 corticosteroids Drugs 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
125000006310 cycloalkyl amino group Chemical group 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
230000003412 degenerative effect Effects 0.000 description 1
230000000593 degrading effect Effects 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
238000011161 development Methods 0.000 description 1
125000004663 dialkyl amino group Chemical group 0.000 description 1
NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
229940038472 dicalcium phosphate Drugs 0.000 description 1
229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
RPNFNBGRHCUORR-UHFFFAOYSA-N diethyl 2-butylpropanedioate Chemical compound CCCCC(C(=O)OCC)C(=O)OCC RPNFNBGRHCUORR-UHFFFAOYSA-N 0.000 description 1
WSQPGAMFLBWEFV-UHFFFAOYSA-N diethyl 2-methyl-2-(4-phenoxyphenoxy)propanedioate Chemical compound C1=CC(OC(C)(C(=O)OCC)C(=O)OCC)=CC=C1OC1=CC=CC=C1 WSQPGAMFLBWEFV-UHFFFAOYSA-N 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
238000009826 distribution Methods 0.000 description 1
150000002019 disulfides Chemical class 0.000 description 1
229960003530 donepezil Drugs 0.000 description 1
229940052760 dopamine agonists Drugs 0.000 description 1
239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
239000000221 dopamine uptake inhibitor Substances 0.000 description 1
239000003651 drinking water Substances 0.000 description 1
235000020188 drinking water Nutrition 0.000 description 1
229950004203 droloxifene Drugs 0.000 description 1
239000000975 dye Substances 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
229940073621 enbrel Drugs 0.000 description 1
239000007920 enema Substances 0.000 description 1
229940079360 enema for constipation Drugs 0.000 description 1
YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
229960005420 etoposide Drugs 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
239000000284 extract Substances 0.000 description 1
229960001419 fenoprofen Drugs 0.000 description 1
229940125753 fibrate Drugs 0.000 description 1
239000000945 filler Substances 0.000 description 1
238000003818 flash chromatography Methods 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
239000012458 free base Substances 0.000 description 1
239000012737 fresh medium Substances 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
239000007789 gas Substances 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
125000005456 glyceride group Chemical group 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
229910052737 gold Inorganic materials 0.000 description 1
239000010931 gold Substances 0.000 description 1
238000005469 granulation Methods 0.000 description 1
230000003179 granulation Effects 0.000 description 1
125000000623 heterocyclic group Chemical group 0.000 description 1
125000000592 heterocycloalkyl group Chemical group 0.000 description 1
229940018991 hyalgan Drugs 0.000 description 1
BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
150000002431 hydrogen Chemical class 0.000 description 1
QJHBJHUKURJDLG-UHFFFAOYSA-N hydroxy-L-lysine Natural products NCCCCC(NO)C(O)=O QJHBJHUKURJDLG-UHFFFAOYSA-N 0.000 description 1
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 1
229960004171 hydroxychloroquine Drugs 0.000 description 1
229960001680 ibuprofen Drugs 0.000 description 1
125000002883 imidazolyl group Chemical group 0.000 description 1
229960003444 immunosuppressant agent Drugs 0.000 description 1
239000003018 immunosuppressive agent Substances 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
229960000905 indomethacin Drugs 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
229940102223 injectable solution Drugs 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
230000009545 invasion Effects 0.000 description 1
PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
125000001786 isothiazolyl group Chemical group 0.000 description 1
229960000991 ketoprofen Drugs 0.000 description 1
DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
229940043355 kinase inhibitor Drugs 0.000 description 1
GXESHMAMLJKROZ-IAPPQJPRSA-N lasofoxifene Chemical compound C1([C@@H]2[C@@H](C3=CC=C(C=C3CC2)O)C=2C=CC(OCCN3CCCC3)=CC=2)=CC=CC=C1 GXESHMAMLJKROZ-IAPPQJPRSA-N 0.000 description 1
229960002367 lasofoxifene Drugs 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
239000004571 lime Substances 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
201000005202 lung cancer Diseases 0.000 description 1
208000020816 lung neoplasm Diseases 0.000 description 1
229910052943 magnesium sulfate Inorganic materials 0.000 description 1
235000019341 magnesium sulphate Nutrition 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
150000002690 malonic acid derivatives Chemical class 0.000 description 1
239000003771 matrix metalloproteinase inhibitor Substances 0.000 description 1
229940121386 matrix metalloproteinase inhibitor Drugs 0.000 description 1
229960003464 mefenamic acid Drugs 0.000 description 1
BRMYZIKAHFEUFJ-UHFFFAOYSA-L mercury diacetate Chemical compound CC(=O)O[Hg]OC(C)=O BRMYZIKAHFEUFJ-UHFFFAOYSA-L 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
230000000673 metalloproteinaselike Effects 0.000 description 1
230000009401 metastasis Effects 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
229940101972 mirapex Drugs 0.000 description 1
238000002156 mixing Methods 0.000 description 1
125000001624 naphthyl group Chemical group 0.000 description 1
229960002009 naproxen Drugs 0.000 description 1
CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
239000006199 nebulizer Substances 0.000 description 1
230000017074 necrotic cell death Effects 0.000 description 1
229960002715 nicotine Drugs 0.000 description 1
SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
230000001590 oxidative effect Effects 0.000 description 1
125000004043 oxo group Chemical group O=* 0.000 description 1
229960001592 paclitaxel Drugs 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
229960002895 phenylbutazone Drugs 0.000 description 1
VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
239000003757 phosphotransferase inhibitor Substances 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
229960002702 piroxicam Drugs 0.000 description 1
QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
229910052697 platinum Inorganic materials 0.000 description 1
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
239000003380 propellant Substances 0.000 description 1
229960002934 propentofylline Drugs 0.000 description 1
238000000746 purification Methods 0.000 description 1
125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
JEXVQSWXXUJEMA-UHFFFAOYSA-N pyrazol-3-one Chemical class O=C1C=CN=N1 JEXVQSWXXUJEMA-UHFFFAOYSA-N 0.000 description 1
125000000714 pyrimidinyl group Chemical group 0.000 description 1
ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
229940116176 remicade Drugs 0.000 description 1
229940113775 requip Drugs 0.000 description 1
229910052703 rhodium Inorganic materials 0.000 description 1
239000010948 rhodium Substances 0.000 description 1
MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 description 1
229960000371 rofecoxib Drugs 0.000 description 1
RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 1
150000003873 salicylate salts Chemical class 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
238000003345 scintillation counting Methods 0.000 description 1
238000012216 screening Methods 0.000 description 1
MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 description 1
229960003946 selegiline Drugs 0.000 description 1
238000013207 serial dilution Methods 0.000 description 1
VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
229960002073 sertraline Drugs 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
150000004760 silicates Chemical class 0.000 description 1
QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
229960002930 sirolimus Drugs 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
229940036220 synvisc Drugs 0.000 description 1
239000003826 tablet Substances 0.000 description 1
229960001685 tacrine Drugs 0.000 description 1
YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
229940000238 tasmar Drugs 0.000 description 1
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
229940063683 taxotere Drugs 0.000 description 1
125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
125000003831 tetrazolyl group Chemical group 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
125000003396 thiol group Chemical group [H]S* 0.000 description 1
125000004568 thiomorpholinyl group Chemical group 0.000 description 1
230000008427 tissue turnover Effects 0.000 description 1
MIQPIUSUKVNLNT-UHFFFAOYSA-N tolcapone Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC(O)=C(O)C([N+]([O-])=O)=C1 MIQPIUSUKVNLNT-UHFFFAOYSA-N 0.000 description 1
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
229940029284 trichlorofluoromethane Drugs 0.000 description 1
239000002753 trypsin inhibitor Substances 0.000 description 1
239000002447 tumor necrosis factor alpha converting enzyme inhibitor Substances 0.000 description 1
229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 description 1
239000002452 tumor necrosis factor alpha inhibitor Substances 0.000 description 1
230000006433 tumor necrosis factor production Effects 0.000 description 1
102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
229960002004 valdecoxib Drugs 0.000 description 1
LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 description 1
OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
229960004528 vincristine Drugs 0.000 description 1
OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1
239000011701 zinc Substances 0.000 description 1
239000011592 zinc chloride Substances 0.000 description 1
235000005074 zinc chloride Nutrition 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/60—Three or more oxygen or sulfur atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Pain & Pain Management (AREA)
Cardiology (AREA)
Immunology (AREA)
Rheumatology (AREA)
Pulmonology (AREA)
Diabetes (AREA)
Psychiatry (AREA)
Heart & Thoracic Surgery (AREA)
Hospice & Palliative Care (AREA)
Psychology (AREA)
Urology & Nephrology (AREA)
Ophthalmology & Optometry (AREA)
Vascular Medicine (AREA)
Obesity (AREA)
Hematology (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

OA1200200030A 1999-08-12 2000-08-03 Pyrimidine-2,4,6-trione metalloproteinase inhibitors. OA12000A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US14854799P	1999-08-12	1999-08-12

Publications (1)

Publication Number	Publication Date
OA12000A true OA12000A (en)	2006-04-18

Family

ID=22526231

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
OA1200200030A OA12000A (en)	1999-08-12	2000-08-03	Pyrimidine-2,4,6-trione metalloproteinase inhibitors.

Country Status (41)

Country	Link
US (1)	US6579982B1 (fr)
EP (1)	EP1202974B1 (fr)
JP (1)	JP2003507371A (fr)
KR (2)	KR20040073608A (fr)
CN (1)	CN1156454C (fr)
AR (1)	AR025091A1 (fr)
AT (1)	ATE309224T1 (fr)
AU (1)	AU773751B2 (fr)
BG (1)	BG106406A (fr)
BR (1)	BR0013081A (fr)
CA (1)	CA2381551A1 (fr)
CO (1)	CO5180629A1 (fr)
CR (1)	CR6565A (fr)
CZ (1)	CZ2002355A3 (fr)
DE (1)	DE60023903D1 (fr)
EA (1)	EA004680B1 (fr)
EC (1)	ECSP003610A (fr)
EE (1)	EE200200069A (fr)
GE (1)	GEP20053424B (fr)
GT (1)	GT200000137A (fr)
HK (1)	HK1045995B (fr)
HN (1)	HN2000000137A (fr)
HR (1)	HRP20020129A2 (fr)
HU (1)	HUP0202501A3 (fr)
IL (1)	IL148035A0 (fr)
IS (1)	IS6248A (fr)
MA (1)	MA26812A1 (fr)
MX (1)	MXPA02001561A (fr)
NO (1)	NO20020662L (fr)
NZ (1)	NZ516562A (fr)
OA (1)	OA12000A (fr)
PA (1)	PA8498701A1 (fr)
PE (1)	PE20010491A1 (fr)
PL (1)	PL353871A1 (fr)
SK (1)	SK1652002A3 (fr)
TN (1)	TNSN00169A1 (fr)
TR (1)	TR200200381T2 (fr)
UY (1)	UY26285A1 (fr)
WO (1)	WO2001012611A1 (fr)
YU (1)	YU6602A (fr)
ZA (1)	ZA200201070B (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6858598B1 (en)	1998-12-23	2005-02-22	G. D. Searle & Co.	Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6833373B1 (en)	1998-12-23	2004-12-21	G.D. Searle & Co.	Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
MXPA03003735A (es) *	2000-10-26	2003-07-28	Pfizer Prod Inc	Inhibidores de espiropirimidin-2,4,6-triona metaloproteinasas.
US6841671B2 (en)	2000-10-26	2005-01-11	Pfizer Inc.	Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
CZ20031069A3 (cs) *	2000-10-26	2004-05-12	Pfizeráproductsáinc	Pyrimidin@@Ź@Ź@@trionové inhibitory metaloproteinasy
PA8539501A1 (es)	2001-02-14	2002-09-30	Warner Lambert Co	Compuestos triazolo como inhibidores de mmp
DOP2002000332A (es)	2001-02-14	2002-08-30	Warner Lambert Co	Inhibidores de piridina de metaloproteinasas de la matriz
WO2002064578A1 (fr)	2001-02-14	2002-08-22	Warner-Lambert Company Llc	Benzo-thiadiazines inhibitrices des metalloproteinases matricielles
EP1368323B1 (fr)	2001-02-14	2010-06-30	Warner-Lambert Company LLC	Pyrimidine comme inhibiteurs de la m talloprot inase de matrice
DOP2002000333A (es)	2001-02-14	2002-09-30	Warner Lambert Co	Derivados de acido isoftalico como inhibidores de metaloproteinasas de la matriz
US6924276B2 (en)	2001-09-10	2005-08-02	Warner-Lambert Company	Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors
JP2003081838A (ja) *	2001-09-11	2003-03-19	Rohto Pharmaceut Co Ltd	グルコサミン製剤
EP1434585A1 (fr)	2001-10-12	2004-07-07	Warner-Lambert Company LLC	Inhibiteurs de metalloproteinase matricielle (mmp) a base d'alkyne
US6962922B2 (en)	2001-10-12	2005-11-08	Warner-Lambert Company Llc	Alkynylated quinazoline compounds
US6936620B2 (en)	2001-12-20	2005-08-30	Bristol Myers Squibb Company	Barbituric acid derivatives as inhibitors of TNF-α converting enzyme (TACE) and/or matrix metalloproteinases
US6894057B2 (en)	2002-03-08	2005-05-17	Warner-Lambert Company	Oxo-azabicyclic compounds
AU2003220401A1 (en)	2002-03-18	2003-10-08	Bristol-Myers Squibb Company	Uracil derivatives as inhibitors of tnf-alpha converting enzyme (tace) and matrix metalloproteinases
WO2003090751A1 (fr) *	2002-04-26	2003-11-06	Pfizer Products Inc.	Inhibiteurs de metalloproteinase a base de pyrimidine-2, 4, 6-trione
EP1501834B1 (fr) *	2002-04-26	2005-09-07	Pfizer Products Inc.	Inhibiteurs de la triaryl-oxy-aryl-spiro-pyrimidine-2, 4, 6-trione metalloproteinase
DE60302150D1 (en) *	2002-04-26	2005-12-08	Pfizer Prod Inc	N-substituiete heteroaryloxy-aryl-spiro-pyrimidine-2,4,6-trion metalloproteinase inhibitoren
NI200300045A (es) *	2002-04-26	2005-07-08	Pfizer Prod Inc	Inhibidores de triariloxiariloxipirimidin-2,4,6-triona de metaloproteinasa.
WO2004014375A2 (fr)	2002-08-13	2004-02-19	Warner-Lambert Company Llc	Inhibiteurs de metalloprotease bicycliques condenses
AU2003250470A1 (en)	2002-08-13	2004-02-25	Warner-Lambert Company Llc	Pyrimidinone fused bicyclic metalloproteinase inhibitors
JP2006504665A (ja)	2002-08-13	2006-02-09	ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー	マトリックスメタロプロテイナーゼ阻害剤としてのアザイソキノリン誘導体
EP1537098A1 (fr)	2002-08-13	2005-06-08	Warner-Lambert Company LLC	Derives monocycliques en tant qu'inhibiteurs de metalloproteinases matricielles
BR0313384A (pt)	2002-08-13	2005-07-12	Warner Lambert Co	Derivados de cromona como inibidores de metaloproteinases de matriz
JP2006500351A (ja)	2002-08-13	2006-01-05	ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー	マトリックスメタロプロテアーゼ−１３阻害剤としてのピリミジン−２，４−ジオン誘導体
WO2004014378A1 (fr)	2002-08-13	2004-02-19	Warner-Lambert Company Llc	Derives de 3-isoquinolinone utilises comme inhibiteurs de metalloprotease de matrice
WO2004014909A1 (fr)	2002-08-13	2004-02-19	Warner-Lambert Company Llc	Derives fusionnes de la tetrahydropyridine inhibiteurs de la metalloprotease matricielle
WO2004014908A1 (fr)	2002-08-13	2004-02-19	Warner-Lambert Company Llc	Inhibiteurs de metalloproteinases heterobicycliques
PA8578101A1 (es)	2002-08-13	2004-05-07	Warner Lambert Co	Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz
WO2004084903A1 (fr) *	2003-03-27	2004-10-07	F. Hoffmann-La Roche Ag	Utilisation d'une trioxopyrimidine pour le traitement et la prevention de l'angiogenese pathologique oculaire
WO2004084902A1 (fr) *	2003-03-28	2004-10-07	F. Hoffmann-La Roche Ag	Utilisation d'une trioxopyrimidine dans le traitement de lesions chroniques
WO2004089294A2 (fr)	2003-04-04	2004-10-21	Incyte Corporation	Compositions, procedes et kits relatifs au clivage de her-2
US20050107350A1 (en) *	2003-08-22	2005-05-19	Pharmacia Corporation	Method for the treatment or prevention of bone disorders with a cyclooxygenase-2 inhibitor alone and in combination with a bone disorder treatment agent and compositions therewith
WO2012014109A1 (fr)	2010-07-30	2012-02-02	Ranbaxy Laboratories Limited	Sulfamides hétérocycliques servant d'inhibiteurs de synthétase d'arn de transfert, destinés à être utilisés en tant qu'agents antibactériens
TW201512171A (zh)	2013-04-19	2015-04-01	Pfizer Ltd	化學化合物
US20150366275A1 (en) *	2014-06-19	2015-12-24	Gyula Cserfoi	Wearable Signaling Device
GB201705255D0 (en)	2017-03-31	2017-05-17	Univ I Tromsø - Norges Arktiske Univ	Bioactive cyclic compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ334253A (en) *	1996-08-28	2000-11-24	Procter & Gamble	N-hydroxy 1-[(4-methoxyphenyl)sulfonyl]-4-benzyloxycarbonyl-piperazine 2-carboxamide and derivatives thereof for treating musculoskeletal disease or cachexia
BR9810450A (pt) *	1997-06-21	2000-09-05	Roche Diagnostics Gmbh	Derivados de ácido barbitúrico com atividade antimetastática e antitumor

2000
- 2000-07-20 HN HN2000000137A patent/HN2000000137A/es unknown
- 2000-07-20 PA PA20008498701A patent/PA8498701A1/es unknown
- 2000-08-03 NZ NZ516562A patent/NZ516562A/xx unknown
- 2000-08-03 KR KR10-2004-7011899A patent/KR20040073608A/ko not_active Ceased
- 2000-08-03 EP EP00946235A patent/EP1202974B1/fr not_active Expired - Lifetime
- 2000-08-03 AU AU60105/00A patent/AU773751B2/en not_active Ceased
- 2000-08-03 OA OA1200200030A patent/OA12000A/en unknown
- 2000-08-03 AT AT00946235T patent/ATE309224T1/de not_active IP Right Cessation
- 2000-08-03 CN CNB008113920A patent/CN1156454C/zh not_active Expired - Fee Related
- 2000-08-03 HU HU0202501A patent/HUP0202501A3/hu unknown
- 2000-08-03 YU YU6602A patent/YU6602A/sh unknown
- 2000-08-03 SK SK165-2002A patent/SK1652002A3/sk unknown
- 2000-08-03 EA EA200200058A patent/EA004680B1/ru not_active IP Right Cessation
- 2000-08-03 EE EEP200200069A patent/EE200200069A/xx unknown
- 2000-08-03 BR BR0013081-8A patent/BR0013081A/pt not_active IP Right Cessation
- 2000-08-03 TR TR2002/00381T patent/TR200200381T2/xx unknown
- 2000-08-03 MX MXPA02001561A patent/MXPA02001561A/es active IP Right Grant
- 2000-08-03 HK HK02107534.6A patent/HK1045995B/zh not_active IP Right Cessation
- 2000-08-03 HR HR20020129A patent/HRP20020129A2/xx not_active Application Discontinuation
- 2000-08-03 CZ CZ2002355A patent/CZ2002355A3/cs unknown
- 2000-08-03 DE DE60023903T patent/DE60023903D1/de not_active Expired - Lifetime
- 2000-08-03 CA CA002381551A patent/CA2381551A1/fr not_active Abandoned
- 2000-08-03 WO PCT/IB2000/001090 patent/WO2001012611A1/fr not_active Ceased
- 2000-08-03 IL IL14803500A patent/IL148035A0/xx unknown
- 2000-08-03 PL PL00353871A patent/PL353871A1/xx not_active Application Discontinuation
- 2000-08-03 KR KR1020027001880A patent/KR20020047119A/ko not_active Abandoned
- 2000-08-03 GE GE4688A patent/GEP20053424B/en unknown
- 2000-08-03 JP JP2001517509A patent/JP2003507371A/ja active Pending
- 2000-08-04 CO CO00058849A patent/CO5180629A1/es not_active Application Discontinuation
- 2000-08-09 EC EC2000003610A patent/ECSP003610A/es unknown
- 2000-08-09 UY UY26285A patent/UY26285A1/es not_active Application Discontinuation
- 2000-08-09 US US09/635,156 patent/US6579982B1/en not_active Expired - Fee Related
- 2000-08-10 AR ARP000104130A patent/AR025091A1/es unknown
- 2000-08-10 PE PE2000000811A patent/PE20010491A1/es not_active Application Discontinuation
- 2000-08-10 GT GT200000137A patent/GT200000137A/es unknown
- 2000-08-11 TN TNTNSN00169A patent/TNSN00169A1/fr unknown
2002
- 2002-01-25 IS IS6248A patent/IS6248A/is unknown
- 2002-01-29 CR CR6565A patent/CR6565A/es not_active Application Discontinuation
- 2002-02-07 ZA ZA200201070A patent/ZA200201070B/en unknown
- 2002-02-07 MA MA26512A patent/MA26812A1/fr unknown
- 2002-02-11 NO NO20020662A patent/NO20020662L/no not_active Application Discontinuation
- 2002-02-12 BG BG06406A patent/BG106406A/xx unknown

Also Published As

Publication number	Publication date
ECSP003610A (es)	2002-03-25
HK1045995B (zh)	2004-12-31
EP1202974B1 (fr)	2005-11-09
EP1202974A1 (fr)	2002-05-08
TNSN00169A1 (fr)	2005-11-10
HK1045995A1 (en)	2002-12-20
ZA200201070B (en)	2003-04-30
WO2001012611A1 (fr)	2001-02-22
MA26812A1 (fr)	2004-12-20
UY26285A1 (es)	2001-03-16
CR6565A (es)	2004-02-23
PL353871A1 (en)	2003-12-01
IL148035A0 (en)	2002-09-12
CA2381551A1 (fr)	2001-02-22
HUP0202501A3 (en)	2003-02-28
CN1368963A (zh)	2002-09-11
CZ2002355A3 (cs)	2002-07-17
SK1652002A3 (en)	2002-09-10
YU6602A (sh)	2004-11-25
BR0013081A (pt)	2002-04-23
AR025091A1 (es)	2002-11-06
PA8498701A1 (es)	2002-08-26
EA004680B1 (ru)	2004-06-24
NO20020662L (no)	2002-04-09
NZ516562A (en)	2003-06-30
AU773751B2 (en)	2004-06-03
NO20020662D0 (no)	2002-02-11
PE20010491A1 (es)	2001-04-25
HUP0202501A2 (hu)	2002-12-28
ATE309224T1 (de)	2005-11-15
TR200200381T2 (tr)	2002-05-21
CO5180629A1 (es)	2002-07-30
AU6010500A (en)	2001-03-13
HN2000000137A (es)	2001-02-02
KR20020047119A (ko)	2002-06-21
EE200200069A (et)	2003-04-15
GT200000137A (es)	2002-02-01
DE60023903D1 (de)	2005-12-15
JP2003507371A (ja)	2003-02-25
CN1156454C (zh)	2004-07-07
BG106406A (en)	2002-09-30
HRP20020129A2 (en)	2004-04-30
IS6248A (is)	2002-01-25
US6579982B1 (en)	2003-06-17
EA200200058A1 (ru)	2002-06-27
MXPA02001561A (es)	2002-07-02
KR20040073608A (ko)	2004-08-19
GEP20053424B (en)	2005-01-25

Publication	Publication Date	Title
OA12000A (en)	2006-04-18	Pyrimidine-2,4,6-trione metalloproteinase inhibitors.
US6608104B2 (en)	2003-08-19	Gem substituted hydroxamic acids
US6214870B1 (en)	2001-04-10	Dioxocyclopentyl hydroxamic acids
US6156798A (en)	2000-12-05	Cyclobutyl-aryloxyarylsulfonylamino hydroxamic acid derivatives
CA2327758C (fr)	2006-01-10	Hydroxamides de l'acide (4-arylsulfonylamino)-tetrahydropyrane-4-carboxylique
AU740664B2 (en)	2001-11-08	Bicyclic hydroxamic acid derivatives
US6114361A (en)	2000-09-05	5-oxo-pyrrolidine-2-carboxylic acid hydroxamide derivatives
WO2002034726A9 (fr)	2003-03-06	Inhibiteurs de la pyrimidine-2,4,6-trione metalloproteinase
HUP0301577A2 (hu)	2003-11-28	Spiro-pirimidin-2,4,6-trion metalloproteináz inhibitorok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
US6458822B2 (en)	2002-10-01	2-oxo-imidazolidine-4-carboxylic acid hydroxamide compounds that inhibit matrix metalloproteinases
EP1181285B1 (fr)	2003-10-08	Hydroxamides d'acide 3-(arylsulfonylamino)-tetrahydrofurane-3-carboxylique
US6387901B1 (en)	2002-05-14	Alkyne containing metalloproteinase inhibitors
US6197810B1 (en)	2001-03-06	3-(arylsulfonylamino)-tetrahydropyran-3-carboxylic acid hydroxamides